Products from TargetMol
TargetMol, based in Boston, Massachusetts, was founded in 2015 and is a drug screening expert in the life science community. The company offers diverse compound libraries, including FDA-approved libraries, and covers a broad spectrum of small molecule compounds such as inhibitors and agonists as well as recombinant proteins and natural products. TargetMol's products are used by researchers worldwide in areas such as cancer research, neurobiology, inflammation, immunology and metabolism.
More information at: www.targetmol.com
No results were found for the filter!
NEW
Lulizumab
Item number: TGM-T76817-10mg
Description: Lulizumab, a humanized anti-CD28 recombinant antibody, functions as a selective CD28 blockade. By specifically targeting CD28 signaling, it inhibits T cell activation [1]. Target: Immunology/Inflammation related
From 274.00€
*
NEW
Lumretuzumab
Item number: TGM-T76818-10mg
Description: Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity for the study of advanced HER3-positive solid tumors and breast cancer. Target: EGFR. References: Schneeweiss A, et al. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody...
| Keywords: | RG7116 , RO5479599 , RO-5479599 , Anti-Human ERBB3 Recombinant Antibody , RG-7116 |
From 215.00€
*
NEW
Namilumab
Item number: TGM-T76820-10mg
Description: Namilumab (AMG203) is a humanised IgG1 monoclonal antibody that neutralises GM-CSF (granulocyte-macrophage colony-stimulating factor) by binding to its ligand with high affinity, and is used in the study of rheumatoid arthritis and active axial spondyloarthritis. Target: c-Fms. References: Huizinga TWJ,...
| Keywords: | AMG203 , Anti-Human CSF2 Recombinant Antibody , AMG-203 |
From 233.00€
*
NEW
Ocaratuzumab
Item number: TGM-T76821-10mg
Description: Ocaratuzumab (AME 133v), an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, demonstrates enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) [1] [2] with a dissociation constant (Kd) of approximately 100 pM. Target: Immunology/Inflammation related
From 274.00€
*
NEW
Ruplizumab
Item number: TGM-T76825-10mg
Description: Ruplizumab (BG 9588) is a humanized IgG1kappa-like monoclonal antibody against CD40L. Ruplizumab is used in the study of neurological and immune system disorders. Target: TNF. References: Chamberlain C, et al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated...
| Keywords: | BG9588 , BG 9588 , Anti-Human CD40L Recombinant Antibody |
From 187.00€
*
NEW
Toralizumab
Item number: TGM-T76834-10mg
Description: Toralizumab (IDEC-131), a humanized monoclonal antibody (mAb) directed against CD40L (CD154), consists of human gamma 1 heavy chains and human kappa light chains. Specifically targeting CD40L on T cells, it inhibits CD40 signaling, acting as an immunosuppressive agent with potential applications in...
| MW: | 148.43 kD |
From 274.00€
*
NEW
Visilizumab
Item number: TGM-T76839-10mg
Description: Visilizumab is a humanized IgG2 monoclonal antibody engineered to target the CD3 antigen on T-cells while exhibiting low Fc receptor binding activity to minimize activation-induced cytotoxicity. this unique design potentially suppresses the body's immune response through the modulation of T-cell...
| Keywords: | Anti-Human CD3E Recombinant Antibody , HuM291 |
From 310.00€
*
NEW
Imdevimab
Item number: TGM-T76847-10mg
Description: Imdevimab (REGN10987), a human monoclonal antibody designed to neutralize the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging COVID-19 variants. When combined with Casirivimab, it effectively reduces viral load and enhances disease management [1]. Target: SARS-CoV
From 274.00€
*
NEW
Atoltivimab
Item number: TGM-T76848-10mg
Description: Atoltivimab (REGN3470), also known as maftivimab/odesivimab (Inmazeb), represents the first monoclonal antibody approved by the Food and Drug Administration (FDA) to combat Zaire ebolavirus (EBOV) infection [1]. Target: Virus Protease
From 233.00€
*
NEW
Enavatuzumab
Item number: TGM-T76865-10mg
Description: Enavatuzumab (PDL192) is a humanized monoclonal antibody targeting the TWEAK receptor (TWEAKR), with anti-tumor activity. It induces tumor growth inhibition by recruiting and activating myeloid effectors to kill tumor cells. It is used in late-stage solid tumor research. Target: TNF. References: Ye S,...
| Keywords: | PDL192 , Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody , ABT361 , PDL-192 , ABT-361 |
From 215.00€
*
NEW
Neihulizumab
Item number: TGM-T76872-10mg
Description: Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that specifically binds to human CD162 (PSGL-1). this binding leads to the downregulation and apoptosis of activated T cells, a mechanism currently in clinical development for the treatment of steroid-refractory acute graft-versus-host...
| Keywords: | ALTB-168 , Anti-PSGL1/CD162 Reference Antibody |
From 215.00€
*
NEW
Abelacimab
Item number: TGM-T76894-10mg
Description: Abelacimab (MAA868), a fully human IgG1 monoclonal antibody that binds to and blocks the activation of FXI, is an anticoagulant used in the study of thromboembolic diseases. Target: Factor Xa. References: Koch AW, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on...
| Keywords: | MAA 868 , MAA868 |
From 215.00€
*